Press release
AFFiRiS AG successfully raises €10m equity financing
• € 10m additional capital raised• Strengthened management team, Günther Staffler appointed as Chief Technology Officer
• Noel Barrett appointed as additional member of the supervisory board
AFFiRiS AG has successfully completed its capital increase and raises an additional € 10m from existing investors and FCPB Affi GmbH. The Supervisory Board has appointed Günther Staffler as Chief Technology Officer. Noel Barrett has joined the Supervisory Board as of 15 June 2016.
In an extraordinary shareholders' meeting on 29 April 2016 the shareholders of the company have agreed to a capital increase of € 10m. The new shares have equally been subscribed by the two major investors of the company, Santo Holding – the family office of the Strüngmann family – , the MIG Funds advised by MIG Verwaltungs AG and new investor FCPG Affi GmbH. In the ordinary shareholders' meeting on 15 June 2016 the shareholders also elected Noel Barrett as additional member of the Supervisory Board. He replaces Dr. Frank Mattner whose tenure as supervisory board member has ended on 31 December 2015.
Noel Barrett has more than 30 years’ experience in the vaccines and biotechnology industry with management responsibilities covering the complete development process required to bring vaccine products to the market. In his last position at Baxter Healthcare, Noel Barrett was Vice President, Global R&D Vaccines and has successfully overseen the development of numerous vaccine candidates through preclinical and clinical development.
Michael Motschmann, Chairman of the Supervisory Board of AFFiRiS commented: "We are excited to welcome Noel Barrett to the Supervisory Board of AFFiRiS. His product development expertise will be tremendously valuable as the company focuses on advancing its projects in clinical development."
The company has decided to adapt its management structure to focus on development, both preclinical and clinical of its projects. All preclinical development will be led by Günther Staffler (48) whom the Supervisory Board has appointed as Chief Technology Officer and member of the executive board of AFFiRiS. Günther Staffler has previously been responsible as Head of Immunology for the preclinical development of its vaccine candidates AT04A and AT06A in Hypercholesterolemia and Atherosclerosis prevention which are currently being tested in Phase 1 clinical development. The company also announces the departure of Achim Schneeberger, previously Chief Medical Officer and Arne von Bonin, Chief Scientific Officer.
AFFIRIS commenced Phase 1 clinical development of its Hypercholesterolemia and Atherosclerosis prevention vaccine candidates AT04A and AT06A and expects data from this study in Q1 2017. AT04A and AT06A are vaccine candidates from the next generation AFFITOME® technology and target PCSK9, an enzyme which plays a role in the lipid metabolism of the liver. If PCSK9 is blocked, more LDL receptors will be present on the surface of the liver and will remove more LDL cholesterol from the blood. Therefore, blocking PCSK9 can lower blood cholesterol levels.
About AFFiRiS AG:
On the basis of its proprietary patented AFFITOME®-technolgy, AFFiRiS develops tailor-made therapeutic peptide vaccines against chronic diseases. Its clinical pipeline consists of 3 drug candidates against Parkinson’s, MSA and Hypercholesterolemia. Further vaccine candidates against diabetes, allergies, asthma as well as Huntington's disease are in preclinical development. AFFiRiS has been able to attract funding of approx. € 130m to date, half of which comes from license income and government grants. AFFiRiS currently employs 60 highly qualified staff at the Campus Vienna Biocenter in Vienna, Austria.
www.affiris.com
Contact AFFiRiS AG:
Bettina Wessa
Karl-Farkas-Gasse 22
1030 Vienna, Austria
T +43 / (0)1 / 798 15 75 - 300
E bettina.wessa@affiris.com
W http://www.affiris.com
Distribution:
PR&D – Public Relations for Research & Education
Mariannengasse 8
1090 Vienna, Austria
T +43 / (0)1 / 505 70 44
E contact@prd.at
W http://www.prd.at
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release AFFiRiS AG successfully raises €10m equity financing here
News-ID: 345631 • Views: …
More Releases from AFFiRiS AG
Vaccine Development Boosted With 10 Mio. Euros at AFFiRiS AG
Vaccine Specialist AFFiRiS AG successfully completes Financing Round
• € 10m additional capital raised
• Supervisory Board appoints Oliver Siegel as Chief Executive Officer
• Prof. Dr. Christoph Huber elected to Supervisory Board
AFFiRiS AG has successfully completed its capital increase and raises an additional € 10m from existing investors. The Supervisory Board has appointed Oliver Siegel as Chief Executive Officer and Dr. Arne von Bonin as Chief Scientific Officer. Prof. Dr. Christoph Huber has joined the…
New board member joins AFFiRiS AG
Vienna, 9. September 2014 – AFFiRiS AG today announced the appointment of Oliver Siegel as a new member of the Executive Management Board. He will take over responsibility for Business Development, Finance and Administration. The appointment of the international experienced transaction expert extends the know-how of the board with a focus on partnering and business operations. Oliver Siegel will expend his experience gained at leading international investment banks to focus…
AFFiRiS AG: ALZHEIMER'S VACCINE AD02 ALREADY IN CLINICAL PHASE II
Vienna (Austria), 23. April 2010: AFFiRiS AG's clinical Alzheimer's vaccine candidate AD02 has already progressed to phase II clinical testing. It may therefore be possible to confirm the efficacy of the vaccine as early as during 2012. Indeed the start of this efficacy study comes only five months after the completion of the corresponding phase I study. The company is active in several disease areas and is currently developing a…
Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing
AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing
Vienna, November 18, 2009: AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. This decision by the company immediately follows the completion of…
More Releases for Noel
New Fantasy Adventure The Rushing Wind by Mike Noel-Smith Takes Readers on a Jou …
Image: https://www.globalnewslines.com/uploads/2025/06/1750775408.jpg
Author Mike Noel-Smith unveils The Rushing Wind, [https://www.amazon.com/Rushing-Wind-Journey-Through-Destiny-ebook/dp/B0DZQC24TM/] a thrilling and thought-provoking novel that intertwines historical events, mystical encounters, and spiritual discovery. This compelling work of fantasy and historical fiction follows a soul's extraordinary journey through time, guided by an ancient dragon named Ceres, revealing secrets of the cosmos and human destiny.
Blending mythology, ancient civilizations, and metaphysical insights, The Rushing Wind takes readers from the sands of Ancient Egypt…
Noel Deyzel's Academy: Revolutionizing Fitness Coaching Through Technology and P …
Image: https://www.getnews.info/uploads/0e9bb525d476bbac5c12564fd5eba448.jpg
The fitness world is rapidly evolving, with new approaches and technologies emerging constantly. At the forefront is Noel Deyzel's Academy, a fitness coaching service designed to help individuals worldwide reach their physique goals. Offering personalized workout and nutrition plans, continuous progress tracking, and unmatched accountability, Noel Deyzel's Academy is a comprehensive solution for sustainable results.
About Noel Deyzel
To understand the value of the academy, it's essential to know Noel Deyzel.…
The Noel Deyzel App is Now Live on the App Stores
Image: https://www.getnews.info/uploads/f32a852eb0b242117294984433e39dea.png
Introduction
The Noel Deyzel App, the ultimate fitness companion, is now available on the App Store and Google Play. Designed to support all workout and nutritional needs, this app offers premium features to help achieve fitness goals.
Why Choose the Noel Deyzel App?
The Noel Deyzel App revolutionizes fitness journeys with advanced features like comprehensive workout tracking, customizable meal plans, professional-grade workout programs, and evidence-based content. Whether a beginner or an experienced…
Silicon Wafer Reclaim Market Size, Share and Forecast By Key Players-Nano Silico …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Silicon Wafer Reclaim market is anticipated to grow at a compound annual growth rate (CAGR) of 7.89% between 2024 and 2031. The market is expected to grow to USD 14.09 Billion by 2024. The valuation is expected to reach USD 23.97 Billion by 2031.
The market for silicon wafer reclaim is expanding significantly due to the growing need for affordable semiconductor materials.…
Boxer Anthony Stallone Patanella to Attend This Week's Birthday Celebration for …
This by-invitation-only event will be held at the world-class speakeasy DOM
Image: https://www.getnews.info/uploads/d66d045897aeb4c07226397dbacdcae5.png
Anthony Stallone Patanella [https://www.anthonypatanella.com/], the iconic boxer and content creator from Toms River, New Jersey, will be in attendance at Hollywood producer and entrepreneur Noel Ashman's birthday celebration in New York City this week.
Image: https://www.getnews.info/uploads/1968a74b1033f435c3c86f889fd53c50.png
Ashman is a multi-award winning producer and director who is also renowned for his acting and entrepreneurial finesse. He has owned some of the world's…
Wafer Recycling Service Market Growing High for Next Decade Return | Optim Wafer …
Latest Study on Industrial Growth of Wafer Recycling Service Market 2023-2029. A detailed study accumulated to offer the Latest insights about acute features of the Wafer Recycling Service market. The report contains different market predictions related to revenue size, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future…